Cargando…
Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
Basal cell carcinoma (BCC) is the most common malignancy worldwide. Fortunately, most tumors are localized and easily amenable to surgical resection or locally destructive treatments. However, a subset of BCCs can become locally advanced or metastatic. The development of small-molecule inhibitors of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785268/ https://www.ncbi.nlm.nih.gov/pubmed/35082923 http://dx.doi.org/10.1177/17588359211066147 |